Abbonarsi

Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignancies - 10/06/22

Doi : 10.1016/j.clinre.2022.101912 
Dominique Béchade a, b, , Carine Bellera c, d, Lisa Gauquelin c, Isabelle Soubeyran e, Pippa McKelvie-Sebileau f, Marc Debled a, François Chomy a, Guilhem Roubaud a, Marianne Fonck a, Simon Pernot a, b, Alexandre Roch g, Anne-Laure Cazeau g
a Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France 
b Univ. Bordeaux, 146 rue Léo Saignat, 33000 Bordeaux, France 
c Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux, France 
d Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000 Bordeaux, France 
e Department of Pathology, Institut Bergonié, 33076 Bordeaux, France 
f University of Auckland, Auckland, New Zealand 
g Department of Nuclear Medicine, Institut Bergonié, 33076 Bordeaux, France 

Corresponding author: Dominique Béchade, Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux, France.Department of Medical OncologyInstitut Bergonié229 cours de l'ArgonneBordeaux33076France

HIGHLIGHTS

From: Contrast Media Mol Imaging, volume 28, 2018, pages 1-9.
PET-CT has a high sensitivity in assessing cancer extension.
The specificity is much lower, especially for mediastinal lymph nodes in an oncologic context.
Clinical dilemnas may arise during the initial management of a cancer, evaluation of treatment, or monitoring.
In some cases, accurate pathological diagnosis is essential for the initial staging of primary thoracic or extra-thoracic malignancies, or for detecting recurrence in patients with treated malignancies.
From: Am J gastroenterol, volume 95, 2000, pages 2278-2284.
EUS-FNA is a minimally invasive, safe and effective technique.
EUS-FNA shows that hypermetabolic lymph nodes may be due to granulomatous or infectious lesions in an oncological context.
From: Dig Dis Sci, Volume 66, August 2021, Pages 2763-2775.
EUS-FNA is a sensitive, highly specific, and safe method for distinguishing between benign and malignant mediastinal lymphadenopathies.
Our results indicate high sensitivity and excellent specificity.
In our prospective study, we conclude that the diagnostic accuracy of EUS-FNA, without ROSE, is sufficiently robust to avoid the need for a surgical diagnosis.
EUS-FNA made it possible to diagnose 46.8% of granulomatous adenopathies at different stages of the management of thoracic or extra-thoracic cancers.
The combination of PET-CT and EUS-FNA may alter the therapeutic strategy that would have been considered after PET-CT alone.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background

The high sensitivity of PET-CT can identify hypermetabolic mediastinal adenopathies during cancer management, but specificity is low and a biopsy is sometimes required to eliminate benign adenopathies.

Methods

This prospective diagnostic accuracy study included patients with hypermetabolic mediastinal lymphadenopathies revealed on PET-CT during either the initial management of a cancer, treatment evaluation, or monitoring. All patients underwent EUS-FNA. Diagnoses of malignancy based on cytological analysis following EUS-FNA were compared with clinical and radiological follow-up information. The treatment strategy decided before the results of the EUS-FNA pathology reports (Multidisciplinary Team Meeting [MTM-1]) was recorded and compared to the treatment strategy decided once pathological data from EUS-FNA were available (MTM-2).

Main findings

Between 2013 and 2018, 75 patients were included with 47 eligible and evaluable patients. Sensitivity, specificity, and positive and negative predictive values of EUS-FNA were 93%, 100%, 100% and 90%, respectively. The concordance value between the therapeutic strategies determined for MTM-1 and MTM-2 was 44.7%. There were no significant differences in the intensity of fixation on PET-CT between malignant and benign lesions.

Conclusion

The diagnostic accuracy of the minimally invasive EUS-FNA procedure is sufficiently robust to avoid the need for diagnostic surgery. The combination of PET-CT and EUS-FNA may alter the therapeutic strategy that would be considered after PET-CT alone.

REGISTRATION

NCT01892501

Il testo completo di questo articolo è disponibile in PDF.

Keywords : endoscopic ultrasound-guided fine-needle aspiration, mediastinal lymphadenopathy, Positron Emission Tomography - Computed Tomography, clinical impact on cancer management


Mappa


© 2022  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 46 - N° 5

Articolo 101912- Maggio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Endoscopic ultrasound guided fine needle biopsy in patients with suspected gastric linitis plastica
  • Antoine Assaf, Benoit Terris, Lola-Jade Palmieri, Alexandre Rouquette, Frédéric Beuvon, Anna Pellat, Einas Abou Ali, Claire Ginestet, Arthur Belle, Dr Marion Dhooge, Dr Catherine Brezault, Rachel Hallit, Anthony Dohan, Stanislas Chaussade, Romain Coriat, Maximilien Barret
| Articolo seguente Articolo seguente
  • Endoscopic anti-reflux mucosectomy (ARMS): A new therapeutic option in the treatment of gerd in case of oesophageal atresia?
  • Ivann Bouteiller, Marine Guingand, Pascal- Alexandre Thomas, Jean-Michel Gonzalez, Veronique Vitton

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.